Cited by 177Antifungal resistance and susceptibilityAntibiotics Pharmacokinetics and EfficacyFungal Infections and Studies

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis

Open access

Andes, D., Marchillo, K., Conklin, R., Krishna, Gopal, Ezzet, Farkad, Cacciapuoti, Anthony, Loebenberg, David·2004·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.48.1.137-142.2004PMC PMC310197

Open this paper in CoChat — free account

Abstract

Previous in vivo studies have characterized the pharmacodynamic characteristics of two triazole compounds, fluconazole and ravuconazole. These investigations demonstrated that the 24-h area under the concentration-time curve (AUC)/MIC ratio is the critical pharmacokinetic-pharmacodynamic (PK-PD) parameter associated with treatment efficacy. Further analysis demonstrated that a free-drug triazole 24-h AUC/MIC ratio of 20 to 25 was predictive of treatment success in both experimental models and clinical trials. We used a neutropenic murine model of disseminated Candida albicans infection to similarly characterize the time course activity of the new triazole, posaconazole. The PK-PD parameters (percent time above MIC, AUC/MIC ratio, and peak serum drug level/MIC ratio) were correlated with in vivo efficacy, as measured by organism number in kidney cultures after 48 h of therapy. Kinetics and protein binding following oral posaconazole dosing were performed in neutropenic infected mice. Peak levels and AUC from 0 h to ∞ values were nonlinear over the 16-fold dose range studied. Serum drug elimination half-life ranged from 12.0 to 17.7 h. Protein binding was 99%. Single dose postantifungal effect studies demonstrated prolonged suppression of organism regrowth after serum posaconazole levels had fallen below the MIC. Treatment efficacy with the four dosing intervals studied was similar, supporting the AUC/MIC ratio as the PK-PD parameter predictive of efficacy. Nonlinear regression analysis also suggested that the AUC/MIC ratio was strongly predictive of treatment outcomes (AUC/MIC ratio R 2 = 83%; peak serum drug/MIC ratio R 2 = 85%; time that serum levels of posaconazole remained above the MIC R 2 = 65%). Similar studies were conducted with 11 additional C. albicans isolates with various posaconazole susceptibilities (MIC, 0.015 to 0.12 μg/ml) to determine if a similar 24-h AUC/MIC ratio was associated with efficacy. The posaconazole free-drug AUC/MIC ratios were similar for all of the organisms studied (6.12 to 26.7, mean ± SD = 16.9 ± 7.8, P value, 0.42). These free-drug AUC/MIC ratios are similar to those observed for other triazoles in this model.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/aac.48.1.137-142.2004

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736
State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Antibiotics in Laboratory Medicine.
Lorian, V. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-653_4 · Cited by 2,809
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S. R., Leggett, J., Turnidge, J. D., Ebert, S. C., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720
Acute otitis media: management and surveillance in an era of pneumococcal resistance-a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group
Dowell, S. F., Butler, J. C., Giebink, G. S., Jacobs, M. R., Jernigan, D. B., Musher, D. M., Rakowsky, A., & Schwartz, B. (1999) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199901000-00002 · Cited by 505
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
Craig, W. A., & Andes, D. R. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 438
Self-citation
Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis
Redding, S., Smith, J., Farinacci, G., Rinaldi, M., Fothergill, A., Rhine-Chalberg, J., & Pfaller, M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.2.240 · Cited by 269

Show all 26 references

Research works printed but not linked: 2

Craig W. A. and B. Suh. 1996. Protein binding and the antimicrobial effects: methods for the determination of protein binding p. 367-402. In V. Lorian (ed.) Antibiotics in laboratory medicine 4th ed. Williams and Wilkins Baltimore Md.
Kunin, C. M. 1965. The importance of serum protein binding in determining antimicrobial activity and concentration in serum. Clin. Pharmacol. Ther.7:168-179.

Sorted by citations

Items 101–177 of 177

Posaconazole’s impact on prophylaxis and treatment of invasive fungal infections: an update
Smith, W. J., Drew, R. H., & Perfect, J. R. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.7.2.165 · Cited by 16
The pharmacokinetic-pharmacodynamic modeling and cut-off values of tildipirosin againstHaemophilus parasuis
Lei, Z., Liu, Q., Yang, B., Ahmed, S., Cao, J., & He, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.23018 · Cited by 16
Disseminated mycotic infection caused by Westerdykella species in a German Shepherd Dog
Armentano, R. A., Cooke, K. L., & Wickes, B. L. (2013) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.242.3.381 · Cited by 15
Histopathology and antifungal treatment of experimental murine chromoblastomycosis caused by Cladophialophora carrionii
Calvo, E., Pastor, F. J., Salas, V., Mayayo, E., Capilla, J., & Guarro, J. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr537 · Cited by 15
Pharmacokinetic–pharmacodynamic optimization of triazole antifungal therapy
Lewis, R. E. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000399603.91138.e7 · Cited by 14
In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis
Martín‐Vicente, A., Capilla, J., & Guarro, J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01462-15 · Cited by 14
Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy
Gastine, S., Hope, W. W., Hempel, G., Petraitienė, R., Petraitis, V., Mickiene, D., Bacher, J. D., Walsh, T. J., & Groll, A. H. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01574-20 · Cited by 13
Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?
Jauregizar, N., Quindós, G., Gil-Alonso, S., Suárez, E., Sevillano, E., & Eraso, E. (2022) · Journal of Fungi · doi:10.3390/jof8070727 · Cited by 13
In Vitro–In Vivo Correlation of Posaconazole–Amphotericin B Combination against Candida albicans: In Vitro Interacting Concentrations Are Associated with In Vivo Free Drug Levels
Meletiadis, J., Beredaki, M.-I., Elefanti, A., Pournaras, S., & Muller, A. E. (2023) · Journal of Fungi · doi:10.3390/jof9040434 · Cited by 10
Niveau de preuve du suivi thérapeutique pharmacologique du voriconazole
Lesne-Hulin, A., Dailly, É., & Guellec, C. B. (2011) · Therapies · doi:10.2515/therapie/2011009 · Cited by 11
Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease
McCann, S. M., Sinha, J., Wilson, W. S., McKinzie, C. J., Garner, L. M., & González, D. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01254-2 · Cited by 10
The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an In Vitro Pharmacokinetic-Pharmacodynamic Model
Beredaki, M.-I., Arendrup, M. C., Andes, D. R., Mouton, J. W., & Meletiadis, J. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01292-20 · Cited by 10
Self-citation
Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use
Nett, J. E., & Andes, D. R. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch22 · Cited by 10
Self-citation
Actualités sur le posaconazole
Paugam, A. (2007) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2006.11.002 · Cited by 10
Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story
Sheppard, D. C., Campoli, P., & Duarte, R. F. (2014) · Haematologica · doi:10.3324/haematol.2013.100263 · Cited by 10
Antifungal pharmacodynamics: Latin America's perspective
González, J. M., Rodríguez, C. A., Agudelo, M., Zuluaga, A. F., & Vesga, Ó. (2016) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2016.09.009 · Cited by 10
Virulence and antifungal therapy of murine disseminated infection by Rhodotorula mucilaginosa
Pamela Thomson, M., López‐Fernández, L., Guarro, J., & Capilla, J. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.06.005 · Cited by 9
Efficacy of combination therapy of triazole and echinocandin in treatment of invasive aspergillosis: a systematic review of animal and human studies.
Zhang, M., Sun, W., Wu, T. H., Chen, F., Xu, X., Su, X., & Shi, Y. P. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2014.01.18 · Cited by 10
Utilization of nanotechnology and experimental design in the development and optimization of a posaconazole‒calendula oil nanoemulgel for the treatment of mouth disorders
Alissa, M., Hjazi, A. M., Abusalim, G. S., Aloraini, G. S., Alghamdi, S. A., Alharthi, N. S., Rizg, W. Y., Hosny, K. M., & Binmadi, N. O. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1347551 · Cited by 8
COMMENTARY
Watt, K., Cohen‐Wolkowiez, M., Ward, R. M., & Benjamin, D. K. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31824f8426 · Cited by 8
Contribution of a Simple Bioassay in Effective Therapeutic Drug Monitoring of Posaconazole and Voriconazole
Tonini, J., Bailly, S., Gautier‐Veyret, E., Wambergue, C., Pelloux, H., Thiébaut, A., Cornet, M., Stanke‐Labesque, F., & Maubon, D. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000199 · Cited by 8
A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration
Sime, F. B., Stuart, J., Butler, J., Starr, T., Wallis, S. C., Pandey, S., Lipman, J., & Roberts, J. A. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.07.008 · Cited by 8
Tea Saponins: a Novel Stabilizer for Enhancing the Oral Bioavailability of Albendazole Nanocrystals
Lan, S., Chen, K., Feng, L., Sima, P., Ji, X., Wu, F., & Lin, Y. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-024-03015-1 · Cited by 6
Therapeutic efficacy of posaconazole in a murine model of disseminated trichosporonosis
Treviño‐Rangel, R. D. J., Lopez, L. J., Palma‐Nicolás, J. P., Hernández‐Bello, R., González‐González, J. G., & González, G. M. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt466 · Cited by 6
Therapeutic drug monitoring for antifungal triazoles: pharmacologic background and current status
Groll, A. H., & Gastine, S. (2019) · Handbook of analytical separations · doi:10.1016/b978-0-444-64066-6.00009-5 · Cited by 7
From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis
Pea, F. (2020) · Mycoses · doi:10.1111/myc.13121 · Cited by 6
ISCCM Position Statement on the Management of Invasive Fungal Infections in the Intensive Care Unit
Kumar, S., Gupta, S., Chakrabarti, A., Pande, R. K., Bhattacharya, P., Bhosale, S. J., Kumar, A. A., Mishra, V. K., Sinha, S., & Reddy, P. K. (2024) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24747 · Cited by 5
Unlocking the Unreachable: Cationic ThermoSomes for Next-Generation Posaconazole Therapy
Yawalkar, A. N., Phatak, K. M., Sole, S., & Vavia, P. R. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00395 · Cited by 5
Efficacy of two novel antifungal lipopeptides, AF4 and AF5 of bacillomycin D family in murine models of invasive candidiasis, cryptococcosis, and aspergillosis
Paul, R. A., Madduri, M., Kashyap, N., Ramesh, S., Rudramurthy, S. M., & Roy, U. (2024) · Apmis · doi:10.1111/apm.13506 · Cited by 5
Niveau de preuve du suivi thérapeutique pharmacologique du posaconazole
Lefeuvre, S., Jelassi, M., Benlmouden, A., Berge, M., Guellec, C. B., & Billaud, E. M. (2011) · Therapies · doi:10.2515/therapie/2011010 · Cited by 5
Correction of posaconazole concentrations for hypoalbuminemia
Nix, D. E., Sime, F. B., & Roberts, J. A. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70021 · Cited by 5
Disposition of posaconazole after single oral administration in large falcons (Falco spp): Effect of meal and dosage and a non-compartmental model to predict effective dosage
Azmanis, P., Pappalardo, L., Sara, Z. A. J., Silvanose, C., & Naidoo, V. (2021) · Medical Mycology · doi:10.1093/mmy/myab019 · Cited by 4
Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review
Pecho, T., & Zeitlinger, M. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01327-2 · Cited by 4
Antifungal drugs: predicting clinical efficacy with pharmacodynamics
Nailor, M. D., & Chandrasekar, P. H. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.14 · Cited by 4
Alternative approaches to the therapeutic drug monitoring of prophylactic posaconazole in haematology patients
Vyzantiadis, T., Yannaki, E., Oliver, D. A., Markantonatou, A., Bousiou, Z., Louka, A., Zachrou, E., & Johnson, E. M. (2018) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2017.12.005 · Cited by 4
Antifungal Pharmacokinetics and Pharmacodynamics
Andes, D. R., & Lepak, A. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_8 · Cited by 4
Self-citation
Hypoalbuminemia and Posaconazole Therapeutic Drug Monitoring
Nix, D. E., Al‐Obaidi, M. M., & Zangeneh, T. T. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae452 · Cited by 4
Pharmacokinetics and Pharmacodynamics of Azoles
Mouton, J. W. (2007) · CRC Press eBooks · doi:10.3109/9781420017137-20 · Cited by 3
Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients
Ju, C., Lian, Q., Chen, A., Zhao, B., Zhou, S., Cai, Y., Xie, H., Li, W., Li, S., & He, J. (2022) · Medical Mycology · doi:10.1093/mmy/myac041 · Cited by 3
Update on Antifungal Drug Dosing and Therapeutic Drug Monitoring
Trifilio, S. M. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0050-1 · Cited by 3
Ex Vivo Pharmacokinetics and Pharmacodynamics Modeling and Optimal Regimens Evaluation of Cefquinome Against Bovine Mastitis Caused by Staphylococcus aureus
Jiang, L., Xiao, X., Yan, K.-X., Deng, T., & Wang, Z. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.837882 · Cited by 3
Pharmacokinetics and Pharmacodynamics of?Azoles
Mouton, J. W. (2007) · Infectious disease and therapy · doi:10.3109/9781420017137.017 · Cited by 3
Electromembrane Extraction of Posaconazole for Matrix-Assisted Laser Desorption/Ionization Mass Spectrometric Detection
Chen, C., Chen, W., & Chang, S. Y. (2022) · Membranes · doi:10.3390/membranes12060620 · Cited by 2
Cosolvent effects on the complexation of the antifungal propiconazole nitrate with β-cyclodextrin: A combined molecular dynamics and NMR study
Isac, D. L., Tîrnovan, P., Nicolescu, A. F., Fifere, A., Neamțu, A., & Pinteală, M. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107248 · Cited by 2
Les relations pharmacocinétique-pharmacodynamique des antifongiques. Conséquences pour le suivi thérapeutique
Jullien, V., & Lortholary, O. (2006) · Therapies · doi:10.2515/therapie:2006044 · Cited by 2
Pharmacodynamics of antifungal drugs: A strategy to optimize efficacy
Lepak, A. J., & Andes, D. R. (2008) · Current Fungal Infection Reports · doi:10.1007/s12281-008-0003-5 · Cited by 2
Self-citation
Effective concentration-based serum pharmacodynamics for antifungal azoles in a murine model of disseminated Candida albicans infection
Maki, K., & Kaneko, S. (2013) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-013-0122-4 · Cited by 2
Efficacy of Posaconazole in a Murine Model of Systemic Infection by Saprochaete capitata
Pamela Thomson, M., Guarro, J., Mayayo, E., & Capilla, J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01140-15 · Cited by 2
Animal Models to Evaluate Anti-infective Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3323-5_3 · Cited by 2
Self-citation
Analysis of Pharmacokinetic/Pharmacodynamic Parameters and Dosage Regimen of Posaconazole against Candida spp. and Aspergillus spp. Using Monte Carlo Simulation
Wang, Y., Zhao, J., Hu, J., Zhao, X., & Yao, Y. (2020) · Pharmacology & Pharmacy · doi:10.4236/pp.2020.111003 · Cited by 2
Posaconazole Oral Suspension
Cada, D. J., Levien, T. L., & Baker, D. E. (2007) · Hospital Pharmacy · doi:10.1310/hpj4201-57 · Cited by 2
Introduction to the Symposium on Antimicrobial Therapy
Temesgen, Z. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0002 · Cited by 2
Antifungal Pharmacokinetics/Pharmacodynamics
Yagi, Y., & Hamada, Y. (2026) · Medical Mycology Journal · doi:10.3314/mmj.26.003 · Cited by 2
Effects of Obesity on Posaconazole Kinetics in a Patient with Graft versus Host Disease
Pettis, J. J., Hyche, S. R., Logan, K. N., Poursina, A., & Bookstaver, P. B. (2013) · Pharmacology & Pharmacy · doi:10.4236/pp.2013.42034 · Cited by 1
ANTIFUNGAL AGENTS
Groll, A. H., & Walsh, T. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50257-0 · Cited by 1
Antifungal Pharmacokinetics and Pharmacodynamics
Hope, W. W., & Andes, D. R. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3323-5_15 · Cited by 1
Self-citation
Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans
Mueller, S. W., & Kiser, T. H. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0051-0 · Cited by 1
Implications of Evolving and Emerging Pharmacokinetic-Pharmacodynamic Research for Triazoles and Echinocandins
Cota, J. M., Giancola, S. E., Benavides, T. M., & Wiederhold, N. P. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00391-6 · Cited by 1
Azoles
Cottom, L., & McPhee, A. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00133-x · Cited by 1
THE PHARMACOKINETIC-PHARMACODYNAMIC INTERFACE: DETERMINANTS OF ANTI-INFECTIVE DRUG ACTION AND EFFICACY IN PEDIATRICS
Abdel‐Rahman, S. M., & Kearns, G. L. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50252-1 · Cited by 1
Prophylaxis of Invasive Fungal Infections: A Review of the Use of Posaconazole
Collins, C. D., Smith, J. A., & Kaul, D. R. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s1948
Using Antifungal Pharmacodynamics to Improve Patient Outcomes
Wiederhold, N. P. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0010-1
Pharmacological and Host Considerations in the Selection of Dose and Duration of Azole Therapy for Adult Patients
Klepser, M. E. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0089-7
An evaluation of intravenous antifungal medications in patients in a paediatric hospital
Rajan, R. T. (2008) · eSpace (Curtin University)
Current Concepts in Antifungal Pharmacology SYMPOSIUM ON ANTIMICROBIAL THERAPY
Lewis, R. E. (2011)
Antifungals for Candidosis Treatment
Grégio, A. M. T., Veiga, F. F., Rinaldi, M. G., & Bettega, P. V. C. (2015) · Springer eBooks · doi:10.1007/978-3-662-47194-4_4
Impact of in vivo Triazole and Echinocandin Combination Therapy for Invasive
Lepak, A. J., Marchillo, K., VanHecker, J., & Andes, D. R. (2013)
Self-citation
Combating Microbial Resistance to Antimicrobial Agents through Dosing Regimen Optimization
Tam, V. H., & Nikolaou, M. (2008) · Engineering and management innovation series/Engineering and management innovation · doi:10.1201/9780849305696.ch17
Antibiotic Dosing During Continuous Renal Replacement Therapy (CRRT)
Tulli, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-31398-6_1
MAD-ID NEWSLETTER
Retreat, C. (2015)
Pharmacokinetics and Pharmacodynamics of Antifungal Drugs in Children
Padoin, C., Lanternier, F., Lortholary, O., & Jullien, V. (2018) · International Journal of Pharmacokinetics · doi:10.4155/ipk-2017-0016
Applied Antifungal Pharmacometrics: Fluconazole and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis
Clancy, C. J. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4939-1304-6_10
Azoles
Thompson, G. R., & Patterson, T. F. (2009) · Springer eBooks · doi:10.1007/978-90-481-2408-4_15
Antifungal Agents
Groll, A. H., & Walsh, T. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00256-9
The Pharmacokinetic-Pharmacodynamic Interface
Goldman, J. L., Dinh, J., & Abdel‐Rahman, S. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00251-x
15 Antifungal Pharmacokinetics
Farowski, F., & Cornely, O. A. (2013) · Springer eBooks · doi:10.1007/978-3-642-39432-4_15
Cerebral diffusion of posaconazole in an experimental model of disseminated scedosporiosis
Lelièvre, B., Godon, C., Legras, P., Riou, J., Ternant, D., & Bouchara, J.-P. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118918

Authors: Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A., & Loebenberg, D.
Affiliations: University of Wisconsin System (US)
William S. Middleton Memorial Veterans Hospital (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
ORCID: Andes, D.
Krishna, Gopal
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2004-01
Volume: 48
Issue: 1
Pages: 137-142
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.48.1.137-142.2004
PMC: PMC310197
OpenAlex: W2126064588
Cited by: 177
References: 26
Citations by year: 2026: 1 · 2025: 7 · 2024: 5 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 6 · 2019: 5 · 2018: 8 · 2017: 4 · 2016: 5 · 2015: 8 · 2014: 8 · 2013: 12 · 2012: 9
FWCI: 4.47
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Keywords: posaconazole, triazole antifungals, pharmacodynamics, pharmacokinetics, systemic candidiasis, Candida albicans, AUC/MIC ratio, neutropenic mice, free drug concentration, drug-protein binding, elimination half-life, fluconazole, ravuconazole, treatment efficacy prediction, nonlinear pharmacokinetics
MeSH terms: Animals, Antifungal Agents, Candida albicans, Candidiasis, Dose-Response Relationship, Drug, Female, Mice, Inbred ICR, Microbial Sensitivity Tests, Neutropenia, Triazoles, Colony Count, Microbial, Area Under Curve, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks